pioglitazone has been researched along with Sepsis in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male rats were randomly divided into three groups as follows: sham, sepsis, and sepsis + pioglitazone." | 7.81 | Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. ( Gao, M; Jiang, Y; Peng, Y; Xiao, X; Yang, M, 2015) |
| "The insulin sensitizing thiazolidinedione drugs, rosiglitazone and pioglitazone are specific peroxisome proliferator-activated receptor-gamma agonists and reduce pro-inflammatory responses in patients with type 2 diabetes and coronary artery disease, and may be beneficial in sepsis." | 7.80 | Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. ( Chima, R; Kaplan, J; Nowell, M; Zingarelli, B, 2014) |
| "To determine whether peroxisome proliferator-activated receptor (PPAR) gamma ligands improve survival of patients with septic shock we treated a mouse model of sepsis [apolipoprotein (Apo) E) knockout mice] with pioglitazone, a PPAR-gamma ligand." | 7.74 | Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. ( Haraguchi, G; Imai, T; Isobe, M; Kosuge, H; Maejima, Y; Suzuki, J; Yoshida, M, 2008) |
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 5.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| "Pioglitazone improves sepsis-induced organ injury accompanied with anti-inflammatory effects on visceral adipose tissue." | 3.85 | Impact of Pioglitazone on Macrophage Dynamics in Adipose Tissues of Cecal Ligation and Puncture-Treated Mice. ( Kutsukake, M; Matsuda, A; Matsutani, T; Tachikawa, E; Tamura, K; Uchida, E, 2017) |
| "Male rats were randomly divided into three groups as follows: sham, sepsis, and sepsis + pioglitazone." | 3.81 | Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. ( Gao, M; Jiang, Y; Peng, Y; Xiao, X; Yang, M, 2015) |
| "The insulin sensitizing thiazolidinedione drugs, rosiglitazone and pioglitazone are specific peroxisome proliferator-activated receptor-gamma agonists and reduce pro-inflammatory responses in patients with type 2 diabetes and coronary artery disease, and may be beneficial in sepsis." | 3.80 | Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. ( Chima, R; Kaplan, J; Nowell, M; Zingarelli, B, 2014) |
| "Pioglitazone effectively prevents lung injury caused by CLP-induced sepsis by maintaining the anti-inflammatory status of visceral adipose tissue." | 3.80 | Pioglitazone attenuates lung injury by modulating adipose inflammation. ( Kobayashi, M; Kutsukake, M; Matsuda, A; Matsutani, T; Tachikawa, E; Tamura, K; Uchida, E, 2014) |
| " This utilized a single daily dose of pioglitazone for pediatric patients with severe sepsis and septic shock based upon adult and minimal adolescent data." | 3.77 | Optimal study design for pioglitazone in septic pediatric patients. ( Ding, L; Kaplan, J; Sherwin, CM; Spigarelli, MG; Vinks, AA, 2011) |
| "To determine whether peroxisome proliferator-activated receptor (PPAR) gamma ligands improve survival of patients with septic shock we treated a mouse model of sepsis [apolipoprotein (Apo) E) knockout mice] with pioglitazone, a PPAR-gamma ligand." | 3.74 | Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. ( Haraguchi, G; Imai, T; Isobe, M; Kosuge, H; Maejima, Y; Suzuki, J; Yoshida, M, 2008) |
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 1.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsutani, T | 3 |
| Tamura, K | 3 |
| Kutsukake, M | 3 |
| Matsuda, A | 3 |
| Tachikawa, E | 2 |
| Uchida, E | 3 |
| Kaplan, JM | 1 |
| Zingarelli, B | 2 |
| Krallman, K | 1 |
| Tang Girdwood, S | 1 |
| Lagory, D | 1 |
| Mizuno, T | 1 |
| Fei, L | 1 |
| Wong, HR | 1 |
| Vinks, AA | 2 |
| Nakashima, M | 1 |
| Kinoshita, M | 1 |
| Nakashima, H | 1 |
| Kotani, A | 1 |
| Ishikiriyama, T | 1 |
| Kato, S | 1 |
| Hiroi, S | 1 |
| Seki, S | 1 |
| Kaplan, J | 2 |
| Nowell, M | 1 |
| Chima, R | 1 |
| Kobayashi, M | 1 |
| Gao, M | 1 |
| Jiang, Y | 1 |
| Xiao, X | 2 |
| Peng, Y | 1 |
| Yang, M | 1 |
| Shafaroodi, H | 1 |
| Hassanipour, M | 1 |
| Mousavi, Z | 1 |
| Rahimi, N | 1 |
| Dehpour, AR | 1 |
| Sherwin, CM | 1 |
| Ding, L | 1 |
| Spigarelli, MG | 1 |
| Tsujimura, Y | 1 |
| Sasajima, K | 1 |
| Haraguchi, G | 1 |
| Kosuge, H | 1 |
| Maejima, Y | 1 |
| Suzuki, J | 1 |
| Imai, T | 1 |
| Yoshida, M | 1 |
| Isobe, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock[NCT01352182] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We examined the effect of pioglitazone Area under the curve on IL-6 in patients receiving pioglitazone only. (Control subjects did not receive pioglitazone). The pharmacokinetic endpoint was area under the curve (AUC) total/days of pioglitazone administration (NCT01352182)
Timeframe: Evaluation of inflammatory biomarkers will be obtained prior to dosing for the first five days of the study
| Intervention | ng/ml (Least Squares Mean) |
|---|---|
| Pioglitazone Hydrochloride | -1.4425 |
| Normal Standard Care | NA |
The number of hypoglycemic events in pioglitazone vs standard care. Hypoglycemia was defined as blood glucose level that remains <40mg/dl despite dextrose bolus treatment. (NCT01352182)
Timeframe: Assessement over five days
| Intervention | events (Number) |
|---|---|
| Pioglitazone Hydrochloride | 0 |
| Normal Standard Care | 0 |
Pioglitazone concentration as the total area under curve divided by the number of days receiving the drug in subjects who took the drug by mouth versus by naso-gastric tube (NCT01352182)
Timeframe: five days
| Intervention | ng*h/ml (Mean) |
|---|---|
| Pioglitazone Hydrochloride by Mouth | 5363 |
| Pioglitazone Hydrochloride by Nasogastric Tube | 1052 |
ALT levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | U/L (Median) |
|---|---|
| Pioglitazone Hydrochloride | 21.5 |
| Normal Standard Care | 24.5 |
BUN levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 7.5 |
| Normal Standard Care | 10 |
Creatinine levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 0.72 |
| Normal Standard Care | 0.415 |
1 trial available for pioglitazone and Sepsis
| Article | Year |
|---|---|
Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial.
Topics: Critical Illness; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Sepsis | 2018 |
9 other studies available for pioglitazone and Sepsis
| Article | Year |
|---|---|
Impact of Pioglitazone on Macrophage Dynamics in Adipose Tissues of Cecal Ligation and Puncture-Treated Mice.
Topics: Adipokines; Animals; Arginase; Biomarkers; Cecum; Chemokine CCL2; Hypoglycemic Agents; Injections, I | 2017 |
Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism.
Topics: Aging; Animals; CD11b Antigen; Cytokines; Escherichia coli; Escherichia coli Infections; Glucose; In | 2019 |
Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis.
Topics: Adipokines; Animals; Cytokines; Hypoglycemia; Hypoglycemic Agents; I-kappa B Proteins; Inflammation; | 2014 |
Pioglitazone attenuates lung injury by modulating adipose inflammation.
Topics: Acute Lung Injury; Adipose Tissue; Animals; Apoptosis; Disease Models, Animal; Endotoxins; Hypoglyce | 2014 |
Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model.
Topics: Amine Oxidase (Copper-Containing); Animals; Bacterial Translocation; Disease Models, Animal; Interle | 2015 |
The Effects of Sub-Chronic Treatment with Pioglitazone on the Septic Mice Mortality in the Model of Cecal Ligation and Puncture: Involvement of Nitric Oxide Pathway.
Topics: Animals; Cecum; Cytokines; Disease Models, Animal; Guanidines; Ligation; Male; Mice; Nitric Oxide; N | 2015 |
Optimal study design for pioglitazone in septic pediatric patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Diabetes | 2011 |
Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture.
Topics: Adipocytes; Adiponectin; Animals; Cecum; Chemokine CCL2; Disease Models, Animal; Gene Expression; Hy | 2011 |
Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.
Topics: Animals; Apolipoproteins E; Cytokines; Enzyme-Linked Immunosorbent Assay; Hypoglycemic Agents; Infla | 2008 |